The Lancet Publishes Deramiocel Phase 3 Data Showing 54% Slower DMD Decline
Updated
Updated · Yahoo Finance · Jul 29
The Lancet Publishes Deramiocel Phase 3 Data Showing 54% Slower DMD Decline
3 articles · Updated · Yahoo Finance · Jul 29
Summary
HOPE-3 results published in The Lancet showed Capricor's Deramiocel slowed upper-limb function decline by 54% versus placebo in Duchenne muscular dystrophy, meeting the Phase 3 trial's primary endpoint.
The randomized, double-blind, placebo-controlled study enrolled 106 patients, and the journal said independent peer review validated the trial's design, statistical methodology and findings.
Cardiac measures also showed clinically meaningful benefit, supporting what investigators described as a consistent treatment effect across skeletal and heart muscle in a largely non-ambulatory DMD population.
Deramiocel's biologics license application remains under active FDA review, with an advisory committee discussion ahead of an Aug. 22, 2026 PDUFA target action date.
Could peer-reviewed HOPE-3 data and reported cardiac benefits push deramiocel toward FDA approval as the first cell therapy for Duchenne muscular dystrophy?
If deramiocel wins approval, can Capricor overcome launch, pricing, and access hurdles to reach Duchenne patients quickly?